Flexeril (Cyclobenzaprine) is NOT Safe in Children Under 15 Years
The FDA drug label explicitly states that "safety and effectiveness of cyclobenzaprine hydrochloride in pediatric patients below 15 years of age have not been established," making it contraindicated for use in children under this age 1.
FDA-Approved Age Restrictions
The official prescribing information is unequivocal:
- No established safety or efficacy data exists for children under 15 years
- The drug has not undergone adequate pediatric clinical trials in this population
- This is a clear contraindication, not merely a precaution 1
Why This Matters Clinically
Cyclobenzaprine is structurally identical to tricyclic antidepressants like amitriptyline 2, 3. This structural similarity raises several critical safety concerns in pediatric populations:
Anticholinergic Effects:
- Strong anticholinergic properties can cause confusion, hallucinations, urinary retention, and cognitive impairment
- Children may be particularly vulnerable to CNS effects including delirium and altered mental status 4, 3
- The anticholinergic burden in developing brains is poorly understood
Cardiovascular Risks:
- While serious cardiac toxicity appears less common than with true tricyclic antidepressants, tachycardia and blood pressure changes can occur 5
- Pediatric cardiovascular monitoring would be essential but dosing guidelines don't exist
Sedation and CNS Depression:
- Drowsiness occurs in >30% of adult patients 6
- Cyclobenzaprine acts as a potent H1 receptor antagonist, explaining significant sedative effects
- Enhanced CNS depression when combined with other sedatives 1
Available Pediatric Safety Data
A retrospective toxicology review examined 750 cyclobenzaprine exposures, including children as young as 7 months 5. Key findings:
- 26% of exposures were in children ≤6 years
- No deaths occurred
- Common effects: lethargy, tachycardia, agitation
- Serious toxicity was infrequent with doses <1 gram
- However, this was an overdose/exposure study, not therapeutic use data
This toxicology data does NOT establish safety for intentional therapeutic use in children.
Clinical Alternatives for Pediatric Muscle Spasm
When muscle relaxation is needed in children, consider:
- Physical therapy and rest as first-line treatment
- Benzodiazepines (e.g., diazepam) for true muscle spasm, though with caution regarding disinhibition in younger children 2
- Baclofen for spasticity related to CNS injury or neuromuscular disorders 2
- NSAIDs for musculoskeletal pain without the muscle relaxant component
Common Pitfalls to Avoid
- Don't extrapolate adult dosing to adolescents 15-17 years: Even in the approved age range (≥15 years), start with lower doses and titrate carefully
- Don't assume "muscle relaxants" are benign: Cyclobenzaprine carries significant CNS and anticholinergic risks
- Don't combine with other anticholinergic medications: The anticholinergic burden is particularly problematic in children 4
- Don't use for spasticity: The drug is ineffective for cerebral palsy or CNS-related spasticity 1
If Mistakenly Prescribed or Exposure Occurs
- Monitor for anticholinergic toxicity: confusion, hallucinations, urinary retention, tachycardia
- Watch for excessive sedation and respiratory depression
- Most symptoms appear within 4 hours of ingestion 5
- Supportive care is primary treatment
- Contact poison control for guidance
Bottom line: Flexeril should never be prescribed to children under 15 years of age. The lack of safety and efficacy data, combined with known anticholinergic and CNS depressant effects, makes this an inappropriate choice in pediatric populations.